Fact checked byMindy Valcarcel, MS

Read more

November 21, 2022
1 min read
Save

Lung Cancer Awareness Month: FDA approves two therapies, new targets emerge

Fact checked byMindy Valcarcel, MS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

The campaign also promotes the need for screening among eligible populations, as well as the importance of research underway to identify more effective treatments.

Lung cancer scan

In conjunction with Lung Cancer Awareness Month, Healio presents 10 important updates in lung cancer treatment that may be relevant to your practice.

1. New treatments for emerging targets have expanded the armamentarium in lung cancer. Therapies for these less common targets can be highly effective, according to a presenter at Chemotherapy Foundation Symposium. Read more.

2. The FDA approved tremelimumab (Imjudo, AstraZeneca) in combination with durvalumab (Imfinzi, AstraZeneca) and chemotherapy for metastatic non-small cell lung cancer. Read more.

3. The FDA approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals) in combination with platinum-based chemotherapy for first-line treatment of adults with advanced NSCLC. Read more.

4. Some patients with NSCLC who miss radiation treatments may benefit from higher radiation doses during subsequent sessions. Read more.

5. Lower BMI may increase risk for lung cancer, indicating that smoking cessation and maintaining appropriate body weight are critical factors for prevention. Read more.

6. Sotorasib (Lumakras, Amgen) significantly extended PFS compared with standard docetaxel as second-line therapy among patients with KRASG12C-mutated NSCLC. Read more.

7. Younger adults with lung cancer appeared more likely than older adults to have late-stage disease at diagnosis. Read more.

8. About 15% of a large cohort of patients with lung cancer had pathogenic germline variants, nearly all of which could be clinically actionable. Read more.

9. Sublobar resection conferred similar survival outcomes as lobectomy among certain patients with NSCLC. Read more.

10. Most women with lung cancer reported some degree of sexual dysfunction following diagnosis. Read more.